 | • レポートコード：MRC22NVL19417 • 出版社/出版日：LP Information / 2022年10月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥541,680 (USD3,660) | ▷ お問い合わせ |
| Corporate User | ￥1,083,360 (USD7,320) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 世界経済が回復するにつれて、2021年の二次進行型多発性硬化症治療薬の成長は前年から大幅に変化します。LP Information社（米国）の最新の調査によると、世界の二次進行型多発性硬化症治療薬市場規模は、2021年の000ドルから2022年には000ドルに達し、2021年～2022年間に000%の成長が予想されます。2028年には世界の二次進行型多発性硬化症治療薬市場規模が000ドルまで成長し、調査期間中に000%の年平均成長率を記録すると予想されます。 米国の二次進行型多発性硬化症治療薬市場は2021年に000ドルの市場規模が見込まれ、調査期間中は約000%の年平均成長率で成長すると予測されます。中国は世界の二次進行型多発性硬化症治療薬市場の000%のシェアを占め、2028年までに000ドルに達すると展望されます。欧州の二次進行型多発性硬化症治療薬の状況については、ドイツが2028年までに000ドルに達し、調査期間にわたって年平均成長率が000%になると予測されます。アジア地域では、日本と韓国の成長率が、今後5年間でそれぞれ000%と000%になると展望されます。 世界の主要な二次進行型多発性硬化症治療薬プレーヤーとして、AB Science SA、 Actelion Ltd、 Biogen, Inc.、 F. Hoffmann-La Roche Ltd.、 Genzyme Corporation、 Glialogix, Inc.、 Immune Response BioPharma, Inc.、 Innate Immunotherapeutics Ltd、 Kyorin Pharmaceutical Co., Ltd.、 Mallinckrodt Plc、 MedDay SA、 MedImmune, LLC、 Merck KGaA、 Meta-IQ ApS、 Novartis AG、 Opexa Therapeutics, Inc.、 Xenetic Biosciencesなどをカバーしています。売上の面では、世界のトップ2社が2021年に約000%市場シェアを占めています。 当レポートでは、製品タイプ、用途（アプリケーション）、主要メーカー、主要地域および国ごとの二次進行型多発性硬化症治療薬市場の包括的な概要、市場シェア、および成長機会を掲載します。 タイプ別のセグメンテーション：2017年～2022年までの内訳データと2028年まで予測データ イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他 用途（アプリケーション）別のセグメンテーション：2017年～2022年までの内訳データと2028年まで予測データ 病院、診療所、その他 当レポートは次の地域と国の市場規模データを掲載します。 南北アメリカ（米国、カナダ、メキシコ、ブラジル） アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア） 欧州（ドイツ、フランス、イギリス、イタリア、ロシア） 中東/アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国） ********* 目次 ********* レポートの範囲 ・市場の紹介 ・分析対象期間 ・調査の目的 ・調査手法 ・調査プロセスおよびデータソース ・経済指標 ・通貨 エグゼクティブサマリー ・世界市場の概要：二次進行型多発性硬化症治療薬の年間販売量2017-2028、地域別現状・将来分析 ・二次進行型多発性硬化症治療薬のタイプ別セグメント：イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他 ・二次進行型多発性硬化症治療薬のタイプ別販売量：2017-2022年の販売量、売上、市場シェア、販売価格 ・二次進行型多発性硬化症治療薬の用途別セグメント：病院、診療所、その他 ・二次進行型多発性硬化症治療薬の用途別販売量：2017-2022年の販売量、売上、市場シェア、販売価格 企業別世界の二次進行型多発性硬化症治療薬市場 ・企業別のグローバル二次進行型多発性硬化症治療薬市場データ：2020-2022年の年間販売量、市場シェア ・企業別の二次進行型多発性硬化症治療薬の年間売上：2020-2022年の売上、市場シェア ・企業別の二次進行型多発性硬化症治療薬販売価格 ・主要企業の二次進行型多発性硬化症治療薬生産地域、販売地域、製品タイプ ・市場集中度分析 ・新製品および潜在的な参加者 ・合併と買収、拡大 二次進行型多発性硬化症治療薬の地域別レビュー ・地域別の二次進行型多発性硬化症治療薬市場規模2017-2022：年間販売量、売上 ・主要国別の二次進行型多発性硬化症治療薬市場規模2017-2022：年間販売量、売上 ・南北アメリカの二次進行型多発性硬化症治療薬販売の成長 ・アジア太平洋の二次進行型多発性硬化症治療薬販売の成長 ・欧州の二次進行型多発性硬化症治療薬販売の成長 ・中東・アフリカの二次進行型多発性硬化症治療薬販売の成長 南北アメリカ市場 ・南北アメリカの国別の二次進行型多発性硬化症治療薬販売量、売上（2017-2022） ・南北アメリカの二次進行型多発性硬化症治療薬の種類別販売量 ・南北アメリカの二次進行型多発性硬化症治療薬の用途別販売量 ・米国の二次進行型多発性硬化症治療薬市場 ・カナダの二次進行型多発性硬化症治療薬市場 ・メキシコの二次進行型多発性硬化症治療薬市場 ・ブラジルの二次進行型多発性硬化症治療薬市場 アジア太平洋市場 ・アジア太平洋の国別の二次進行型多発性硬化症治療薬販売量、売上（2017-2022） ・アジア太平洋の二次進行型多発性硬化症治療薬の種類別販売量 ・アジア太平洋の二次進行型多発性硬化症治療薬の用途別販売量 ・中国市場の二次進行型多発性硬化症治療薬市場 ・日本市場の二次進行型多発性硬化症治療薬市場 ・韓国市場の二次進行型多発性硬化症治療薬市場 ・東南アジアの二次進行型多発性硬化症治療薬市場 ・インドの二次進行型多発性硬化症治療薬市場 ・オーストラリアの二次進行型多発性硬化症治療薬市場 ・台湾の二次進行型多発性硬化症治療薬市場 欧州市場 ・欧州の国別の二次進行型多発性硬化症治療薬販売量、売上（2017-2022） ・欧州の二次進行型多発性硬化症治療薬の種類別販売量 ・欧州の二次進行型多発性硬化症治療薬の用途別販売量 ・ドイツの二次進行型多発性硬化症治療薬市場 ・フランスの二次進行型多発性硬化症治療薬市場 ・イギリスの二次進行型多発性硬化症治療薬市場 ・イタリアの二次進行型多発性硬化症治療薬市場 ・ロシアの二次進行型多発性硬化症治療薬市場 中東・アフリカ市場 ・中東・アフリカの国別の二次進行型多発性硬化症治療薬販売量、売上（2017-2022） ・中東・アフリカの二次進行型多発性硬化症治療薬の種類別販売量 ・中東・アフリカの二次進行型多発性硬化症治療薬の用途別販売量 ・エジプトの二次進行型多発性硬化症治療薬市場 ・南アフリカの二次進行型多発性硬化症治療薬市場 ・イスラエルの二次進行型多発性硬化症治療薬市場 ・トルコの二次進行型多発性硬化症治療薬市場 ・GCC諸国の二次進行型多発性硬化症治療薬市場 市場の成長要因、課題、動向 ・市場の成長要因および成長機会分析 ・市場の課題およびリスク ・市場動向 製造コスト構造分析 ・原材料とサプライヤー ・二次進行型多発性硬化症治療薬の製造コスト構造分析 ・二次進行型多発性硬化症治療薬の製造プロセス分析 ・二次進行型多発性硬化症治療薬の産業チェーン構造 マーケティング、販売業者および顧客 ・販売チャンネル：直接販売チャンネル、間接販売チャンネル ・二次進行型多発性硬化症治療薬の主要なグローバル販売業者 ・二次進行型多発性硬化症治療薬の主要なグローバル顧客 地域別の二次進行型多発性硬化症治療薬市場予測レビュー ・地域別の二次進行型多発性硬化症治療薬市場規模予測（2023-2028） ・南北アメリカの国別予測 ・アジア太平洋の国別予測 ・欧州の国別予測 ・二次進行型多発性硬化症治療薬のタイプ別市場規模予測 ・二次進行型多発性硬化症治療薬の用途別市場規模予測 主要企業分析 AB Science SA、 Actelion Ltd、 Biogen, Inc.、 F. Hoffmann-La Roche Ltd.、 Genzyme Corporation、 Glialogix, Inc.、 Immune Response BioPharma, Inc.、 Innate Immunotherapeutics Ltd、 Kyorin Pharmaceutical Co., Ltd.、 Mallinckrodt Plc、 MedDay SA、 MedImmune, LLC、 Merck KGaA、 Meta-IQ ApS、 Novartis AG、 Opexa Therapeutics, Inc.、 Xenetic Biosciences ・企業情報 ・二次進行型多発性硬化症治療薬製品 ・二次進行型多発性硬化症治療薬販売量、売上、価格、粗利益（2020-2022） ・主要ビジネス概要 ・最新動向 調査結果および結論 |
As the global economy mends, the 2021 growth of Secondary Progressive Multiple Sclerosis Drug will have significant change from previous year. According to our (LP Information) latest study, the global Secondary Progressive Multiple Sclerosis Drug market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Secondary Progressive Multiple Sclerosis Drug market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Secondary Progressive Multiple Sclerosis Drug market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Secondary Progressive Multiple Sclerosis Drug market, reaching US$ million by the year 2028. As for the Europe Secondary Progressive Multiple Sclerosis Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Secondary Progressive Multiple Sclerosis Drug players cover AB Science SA, Actelion Ltd, Biogen, Inc., and F. Hoffmann-La Roche Ltd., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Secondary Progressive Multiple Sclerosis Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Inebilizumab
GLX-1112
DC-TAB
Etomoxir
IB-MS
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital
Clinic
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
AB Science SA
Actelion Ltd
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co., Ltd.
Mallinckrodt Plc
MedDay SA
MedImmune, LLC
Merck KGaA
Meta-IQ ApS
Novartis AG
Opexa Therapeutics, Inc.
Xenetic Biosciences (UK) Limited
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Country/Region, 2017, 2022 & 2028
2.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type
2.2.1 Inebilizumab
2.2.2 GLX-1112
2.2.3 DC-TAB
2.2.4 Etomoxir
2.2.5 IB-MS
2.2.6 Others
2.3 Secondary Progressive Multiple Sclerosis Drug Sales by Type
2.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2017-2022)
2.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Type (2017-2022)
2.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2017-2022)
2.4 Secondary Progressive Multiple Sclerosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Secondary Progressive Multiple Sclerosis Drug Sales by Application
2.5.1 Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2017-2022)
2.5.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Application (2017-2022)
2.5.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2017-2022)
3 Global Secondary Progressive Multiple Sclerosis Drug by Company
3.1 Global Secondary Progressive Multiple Sclerosis Drug Breakdown Data by Company
3.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Company (2020-2022)
3.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2022)
3.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Company (2020-2022)
3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2022)
3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2022)
3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company
3.4 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Location Distribution
3.4.2 Players Secondary Progressive Multiple Sclerosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Secondary Progressive Multiple Sclerosis Drug by Geographic Region
4.1 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Geographic Region (2017-2022)
4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Geographic Region
4.2 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Country/Region (2017-2022)
4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Country/Region (2017-2022)
4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Country/Region
4.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.4 APAC Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.5 Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.6 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth
5 Americas
5.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country
5.1.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022)
5.1.2 Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022)
5.2 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type
5.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region
6.1.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2017-2022)
6.1.2 APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2017-2022)
6.2 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type
6.3 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Secondary Progressive Multiple Sclerosis Drug by Country
7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022)
7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022)
7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type
7.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug by Country
8.1.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2017-2022)
8.1.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2017-2022)
8.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type
8.3 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug
10.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
10.4 Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Secondary Progressive Multiple Sclerosis Drug Distributors
11.3 Secondary Progressive Multiple Sclerosis Drug Customer
12 World Forecast Review for Secondary Progressive Multiple Sclerosis Drug by Geographic Region
12.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Region
12.1.1 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Region (2023-2028)
12.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Type
12.7 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Application
13 Key Players Analysis
13.1 AB Science SA
13.1.1 AB Science SA Company Information
13.1.2 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Offered
13.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 AB Science SA Main Business Overview
13.1.5 AB Science SA Latest Developments
13.2 Actelion Ltd
13.2.1 Actelion Ltd Company Information
13.2.2 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Offered
13.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Actelion Ltd Main Business Overview
13.2.5 Actelion Ltd Latest Developments
13.3 Biogen, Inc.
13.3.1 Biogen, Inc. Company Information
13.3.2 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered
13.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Biogen, Inc. Main Business Overview
13.3.5 Biogen, Inc. Latest Developments
13.4 F. Hoffmann-La Roche Ltd.
13.4.1 F. Hoffmann-La Roche Ltd. Company Information
13.4.2 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Offered
13.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 F. Hoffmann-La Roche Ltd. Main Business Overview
13.4.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.5 Genzyme Corporation
13.5.1 Genzyme Corporation Company Information
13.5.2 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Offered
13.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Genzyme Corporation Main Business Overview
13.5.5 Genzyme Corporation Latest Developments
13.6 Glialogix, Inc.
13.6.1 Glialogix, Inc. Company Information
13.6.2 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered
13.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Glialogix, Inc. Main Business Overview
13.6.5 Glialogix, Inc. Latest Developments
13.7 Immune Response BioPharma, Inc.
13.7.1 Immune Response BioPharma, Inc. Company Information
13.7.2 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered
13.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Immune Response BioPharma, Inc. Main Business Overview
13.7.5 Immune Response BioPharma, Inc. Latest Developments
13.8 Innate Immunotherapeutics Ltd
13.8.1 Innate Immunotherapeutics Ltd Company Information
13.8.2 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Offered
13.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Innate Immunotherapeutics Ltd Main Business Overview
13.8.5 Innate Immunotherapeutics Ltd Latest Developments
13.9 Kyorin Pharmaceutical Co., Ltd.
13.9.1 Kyorin Pharmaceutical Co., Ltd. Company Information
13.9.2 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Offered
13.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Kyorin Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Kyorin Pharmaceutical Co., Ltd. Latest Developments
13.10 Mallinckrodt Plc
13.10.1 Mallinckrodt Plc Company Information
13.10.2 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Offered
13.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Mallinckrodt Plc Main Business Overview
13.10.5 Mallinckrodt Plc Latest Developments
13.11 MedDay SA
13.11.1 MedDay SA Company Information
13.11.2 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Offered
13.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 MedDay SA Main Business Overview
13.11.5 MedDay SA Latest Developments
13.12 MedImmune, LLC
13.12.1 MedImmune, LLC Company Information
13.12.2 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Offered
13.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 MedImmune, LLC Main Business Overview
13.12.5 MedImmune, LLC Latest Developments
13.13 Merck KGaA
13.13.1 Merck KGaA Company Information
13.13.2 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Offered
13.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Merck KGaA Main Business Overview
13.13.5 Merck KGaA Latest Developments
13.14 Meta-IQ ApS
13.14.1 Meta-IQ ApS Company Information
13.14.2 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Offered
13.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Meta-IQ ApS Main Business Overview
13.14.5 Meta-IQ ApS Latest Developments
13.15 Novartis AG
13.15.1 Novartis AG Company Information
13.15.2 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Offered
13.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Novartis AG Main Business Overview
13.15.5 Novartis AG Latest Developments
13.16 Opexa Therapeutics, Inc.
13.16.1 Opexa Therapeutics, Inc. Company Information
13.16.2 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Offered
13.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Opexa Therapeutics, Inc. Main Business Overview
13.16.5 Opexa Therapeutics, Inc. Latest Developments
13.17 Xenetic Biosciences (UK) Limited
13.17.1 Xenetic Biosciences (UK) Limited Company Information
13.17.2 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Offered
13.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Xenetic Biosciences (UK) Limited Main Business Overview
13.17.5 Xenetic Biosciences (UK) Limited Latest Developments
14 Research Findings and Conclusion